TUBINGEN, Germany and BERLIN, Oct. 15, 2015 /PRNewswire/ -- Amid a torrent of advancements and interest in mRNA science and industry, the 3rd International mRNA Health Conference is set to commence on November 11 - 12, 2015, in Berlin, Germany, providing a gathering point for leading innovators, scientists and academia to chart the future of a technology that is being hailed for its potential to treat a wide range of diseases and medical conditions.
Innovators, scientists, academia and pharmaceutical delegates are expected to attend the conference, which will be held at the Hilton Hotel in Berlin, Germany. The event will provide a platform for international experts to discuss the enormous potential of mRNA for many therapeutic indications and prophylactic use. The meeting will feature approximately 30 speakers, including the key note speakers Nobel Laureate Harald zur Hausen from the German Cancer Research Center (DKFZ) and Jose Esparza from the University of Maryland School of Medicine, who will present and discuss on science, preclinical and clinical research, manufacturing, delivery and regulatory aspects relating to mRNA technologies.
Additionally, a poster session will provide research groups the opportunity to showcase their data to attendees.
The 3rd International mRNA Health Conference is being organized by a joint efforts from BioNTech, CureVac and Moderna, all three biopharmaceutical companies in the field of mRNA-based technology.
Ingmar Hoerr, Initiator of the International mRNA Health Conference and co-founder and CEO of CureVac, commented, "The mRNA industry has experienced a flurry of advancements and interest in recent years, as is evidenced by a number of significant peer-reviewed clinical studies demonstrating the potential and promise of this technology combined with multiple investments totaling more than $1 billion by some of the world's leading multinational corporations and organizations. We truly believe mRNA will result in a new class of drugs and will ultimately transform the treatment of many human diseases and disorders."
Dr. Hoerr continued, "I am very pleased that we could organize the 3rd International mRNA Health Conference in bustling Berlin this year, before returning to the U.S. in 2016. It is a testament to the field of mRNA that its innovators are able to work together so closely, and I look forward to joining with my colleagues in charting a course for 2016 and beyond."
Information on the Conference is available under www.mrna-conference.com.
About the International mRNA Health Conference
The International mRNA Health Conference is a key date for everyone who is working with mRNA for medical purposes or seeking messenger RNA as a novel tool to express proteins directly in situ. Initiated by CureVac and the University of Tubingen in 2013, the event is now in its third year. The Conference provides participants two days of exciting talks and discussions and will foster an environment to build personal connections with others involved in the mRNA industry. Last year's conference brought together nearly 300 attendees from leading international pharmaceutical and biotechnology companies and academic institutions. During the two-day event, colleagues from around the world shared the vanguard of research and technologies poised to unlock the tremendous medical potential of mRNA for a variety of therapeutic indications.
Verena Lauterbach, Manager Communications
CureVac GmbH, Tubingen, Germany
T: +49 (7071) 9883-1756
Tiberend Strategic Advisors, New York
T: +1 (212) 375-2694
SOURCE CureVac AG